Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
peginterferon alfa-2a + ribavirin + epoetin-β
- Development stage
- Phase 4
- Lead developer
- Roche
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Subcutaneous, Oral
01
Overview
This combination therapy regimen consists of peginterferon alfa-2a, ribavirin, and epoetin-β, specifically evaluated for the treatment of chronic hepatitis C in patients coinfected with the Human Immunodeficiency Virus (HIV). Peginterferon alfa-2a is a pegylated interferon biologic that acts as an immunomodulator and antiviral agent by binding to Type I interferon receptors, inducing an antiviral state. Ribavirin is a small molecule nucleoside analog that interferes with viral RNA synthesis and enhances the antiviral effect of interferon. Epoetin-β is a recombinant form of human erythropoietin included in this regimen as supportive care to manage anemia, a frequent side effect of ribavirin-induced hemolysis and interferon-induced bone marrow suppression. The regimen was investigated in the CORAL-2 Phase 4 clinical trial sponsored by Germans Trias i Pujol Hospital, which compared a high-dose induction phase of peginterferon and ribavirin against standard dosing to evaluate viral kinetics and early virological response.
- Brand names
- NeoRecormon
- Other names
- High-dose peginterferon induction therapypeginterferon alfa-2a + ribavirin + epoetin-beta
02
Targets
Erythropoietin ReceptorNS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)IFNAR1 (Interferon alpha/beta receptor 1)IFNAR2 (Interferon alpha/beta receptor subunit 2)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on peginterferon alfa-2a + ribavirin + epoetin-β.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on peginterferon alfa-2a + ribavirin + epoetin-β.